Here's what's pushing biotech lower: Expert

8:42 AM ET Fri, 11 April 2014

I think a lot of it had to do with pricing concerns over Gilead's Sovaldi, says Jason Kolbert, Maxim Group, sharing his thoughts on the future of the biotech sector and pending IPOs.